Older individuals often have reduced nitric oxide production, stiffer blood vessels, and altered responses to vasoactive compounds
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities
Grouping: Control group (physiological saline intra-articular injection), AOD 9604 group (0.25mg/joint), hyaluronic acid (HA) group (0.5mg/joint), AOD 9604+HA combination group
This protects cells from oxidative damage and supports ageing and skin health
Kapoor D, Singh S, Kumar V, Romero R, Prasad R, Singh J
Tailored Treatment